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Permanent brachytherapy has become an accepted
modality for treating localized prostate cancer. Low-risk
disease can be managed with seed implant monotherapy
and high-risk disease with a combination of seeds and
external beam radiotherapy (EBRT)with orwithout hormone
therapy (HT). Treatment of the intermediate-risk group
(IRG) remains controversial. Is monotherapy or combination
treatment the best option? Tomake the case for monotherapy
adequate radiation dose needs to be delivered. In addition to
cancer control, differences between monotherapy and
combination therapy in morbidity, secondary cancer (SC)
risk, and costs also need to be addressed.Disease extent
The current version (1.2013) of the NCCN guidelines
defines an intermediate-risk prostate cancer as stage T2b-c
or Gleason score 7 or a prostate specific antigen (PSA)
10e20 ng/mL (1). Furthermore, these guidelines recom-
mend image-guided radiotherapy (IGRT) with or without
brachytherapy. They do not recommend brachytherapy
alone. The National Cancer Comprehensive Network
(NCCN) IR grouping incorporates a diverse disease spec-
trum. Furthermore, it does not consider how radiation dose
might influence outcomes. The Mount Sinai treatment strat-
ification was developed for brachytherapy and was based
on biochemical recurrence data (2). Patients were desig-
nated as intermediate rsk if they had one intermediate-
risk feature and high risk if they had two or more.
Zelefsky’s classification is very similar (3). Based on this
categorization, patients had been offered monotherapy if
they had only one IRG feature and combination therapy* Corresponding author. Departments of Urology & Radiation
Oncology, Mount Sinai School of Medicine, 350 East 72nd Street, Apt.
8A, New York, NY 10021. Tel.: þ1 845 323-1727.
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http://dx.doi.org/10.1016/j.brachy.2013.07.005if more than one. D’Amico also developed a similar classi-
fication based on radical prostatectomy and radiation data
(D’Amico) (4). Given that these classification systems were
developed over 15 years ago, treatment improvements may
have made them obsolete. For example, the Mount Sinai
system was described just when the first studies on dosing
data became available and thus may or may not be appli-
cable today where higher doses are more commonly
delivered (5).Dose response in intermediate-risk disease
Stock et al. (5) first described a dose response in perma-
nent brachytherapy using CT-based doseevolume histo-
gram data and demonstrated that a post-implant D90 of at
least 140 Gy (I-125, TG43) increased PSA control. As tech-
niques improved, implant D90s and V100 have risen, giving
brachytherapists the opportunity to evaluate the effects of
higher doses in all risk groups. For example, using the
Mount Sinai treatment stratification in IRG prostate cancer,
Kao et al. (6) reported a 5-year biochemical disease-free
survival (ASTRO definition) of 92.8% when patients
received an I-125 implant with a D90 of at least 180 Gy.
Taira et al. (7) reported on 144 IRG patients defining this
group as having only one of the following: Gleason score
of 7, PSA level of 10.1e20.0 ng/mL, or clinical stage of
T2c. Patients were treated with either Pd-103 (prescription
125 Gy) or I-125 (prescription 145 Gy) monotherapy. The
12-year bRFS (PSA # 0.4 ng/mL after nadir) for IRG
was 96.4%. The biochemical performance-free survival rate
for patients with high-quality implants was 98.3% vs.
86.4% for those with less adequate implants ( p ! 0.01)
(Table 1).
In 2006, Stock et al. (8) described the biologic effective
dose (BED) as a means to compare outcomes when
implant or implant plus EBRT was used. Using this meth-
odology, Ho et al. (9) reported on freedom from biochem-
ical failure (FFbF) in IRG patients. The actuarial FFbF at
10 years was 86%. Dose (BED!150 vs. $150 Gy2) washed by Elsevier Inc. All rights reserved.
Table 1
Biochemical freedom from failure in intermediate-risk prostate cancer treated with implant alone
Study Number
Intermediate-risk
group
PSA failure
definition
Free of failure
(%)/time (y)
Median followup
(mo)
Median or mean
D90 (Gy) bFFF dose dependent
Zelefsky et al. (11) 47 NCCN ASTRO 89/5 63 173 No
Dallas et al. (12) 94 NCCN Phoenix 97/NS 30 177 NS
Taira et al. (7) 144 NCCN #0.4 96.4/12 74 116.3%a 98.3/86.4%a
Henry et al. (13) 430 MSKCC (4) Phoenix 73.5/10 58 140 87/77%b
Kao et al. (6) 113 NCCN Phoenix 92.8/5 80 197 Minimum dose 180 Gy
MSKCC 5 Memorial Sloan Kettering Cancer Center; NS 5 Not Stated.
a %Prescription, I-125 145 Gy and Pd-103 125 Gy, greater or less than 116% prescription.
b Dose dependence greater or less than 140 Gy, entire cohort of 1298 patients.
394 N.N. Stone / Brachytherapy 12 (2013) 393e397the only significant predictor of FFbF ( p! 0.001). None
of the other variables (PSA, EBRT, Gleason score, treat-
ment type, hormones, stage, and number of risk factors)
was found to be a statistically significant predictor of
10-year FFbF. Patients receiving the lower dose had
a 63% FFbF compared with 92% for the higher dose
( p!0.001). With similar BED calculations, Stone et al.
(10) described the biochemical freedom from failure
(bFFF) in multicenter investigation of brachytherapy
outcomes. Using NCCN IRG classification, the 10-year
Phoenix bFFF for IRG was 63.6%. Based on three dose
groups, !140, 140e200, and O200 Gy2, bFFF was
52.9%, 74.1%, and, 94.3%, respectively ( p ! 0.0001).
Both BED and EBRT (combination therapy) were the only
significant variables in the proportion hazards model. The
use of neoadjuvant HT did not influence the results
(Table 2).
A recent update from the Mount Sinai Database identi-
fied 690 men categorized by the new NCCN criteria as
IRG and followed a minimum of 2 years (median, 7.2;
range, 2e19 years) (17). Of these 690, 500 had one IRG
risk feature, 187 had two and, three had three features.
Implant only was used in 310 and combination therapy in
380. HT was used in 478/690 (69.2%) for a median of 6
months. The 10-year bFFF (Phoenix) for the entire cohort
was 88.3%. On log rank and cox proportion hazard rates,
the use of HT, EBRT, and NCCN IRG sub-classifications
(1e3 features) were not significant predictors of Phoenix
failure. When dose data were dichotomized to #180 vs.
O180 Gy2 10-year bFFF was 80.8% vs. 91.6%
( p5 0.001; hazard rate, 2.87; 95% confidence interval,
1.5e5.4).Morbidity
Patients who receive combination therapy may have
a greater risk of complications compared with those IRG
patients treated by monotherapy. The ‘‘trifecta’’ for brachy-
therapy patients should be freedom of biochemical relapse,
sexual, and bowel dysfunction. Merrick analyzed 425
patients who underwent brachytherapy alone or in combi-
nation with EBRT (18). With a 6-year followup, 39% of
patients maintained potency after prostate brachytherapy.The preimplant potency score, use of supplemental EBRT,
and diabetes had a negative impact on potency preserva-
tion. The addition of EBRT decreased potency from
52.0% to 26.4% ( p ! 0.001). Wu et al. (19) analyzed
2204 CaPSURE men who received treatment for prostate
cancer. 246 patients received brachytherapy alone and 61
patients had brachytherapy with EBRT. At 20-month fol-
lowup, sexual function was slightly worse with combina-
tion therapy. Snyder evaluated 1063 potent men with
T1eT3 prostate cancer who were treated from 1990 to
2007 with seed implantation alone (69.6%) or combined
modality treatment (30.4%). Patients were required to have
a minimum of 2-year followup and to be off androgen
deprivation therapy (ADT) for a minimum of 1 year (20).
Erectile function was assessed before seed implantation
and at each followup visit using the physician-assigned
Mount Sinai Erectile Function Score. The 5-year and 10-
year actuarial rate of potency preservation was 68.0% and
57.9%, respectively. Five-year potency was 76.4% for
implant alone, 71.0% for implant with EBRT, 62.2% for
implant with ADT, and 57.9% for implant with EBRT
and ADT ( p! 0.001).
The addition of EBRT to brachytherapy can increase
the total radiation dose to the anterior rectal wall. Sarosdy
reported on 177 consecutive patients who underwent
either brachytherapy (56.5%) or combination therapy for
clinical T1eT2 prostate carcinoma between July 1998
and July 2000. All the patients were analyzed with regard
to disease characteristics, treatment details, and complica-
tions requiring unplanned interventions up to 48 months of
followup (21). Colonoscopy with or without fulguration
for rectal bleeding was performed in 37 men at a median
of 17 months, including 15 patients after brachytherapy
and 22 patients after combination therapy ( p 5 0.002).
Combination therapy resulted in fecal diversion in 6.6%
of patients ( p 5 0.021). Merrick mailed 189 prostate bra-
chytherapy patients the Rectal Function Assessment Score
(22,23). Patient perception of overall rectal quality of life
was inversely related to the use of supplemental EBRT
( p 5 0.007). Tran determined rectal complications in
503 men randomized between 125I vs. 103Pd alone
(n 5 290) or to 103Pd with 20 vs. 44 Gy supplemental
EBRT (n 5 213). In a multivariate analysis, the rectal
volume that receivedO100% of the dose was significantly
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395N.N. Stone / Brachytherapy 12 (2013) 393e397predictive of bleeding. Rectal fistulas occurred in two
patients (0.4%), both of whom had received moderate
rectal radiation doses and extensive intervention for rectal
bleeding. In a long-term study of complications following
brachytherapy, Stone also found that the incidence of late
rectal bleeding was associated with greater prostate radia-
tion doses ( p 5 0.023) (24).
Higher radiation doses can also affect urinary function,
potentially increasing the risk of outlet obstruction and
incontinence. Merrick et al. (25) did not find that the addi-
tion of EBRT increased dysuria. However, in a study where
implant patients were compared with controls (no radia-
tion), supplemental EBRT adversely affected function and
incontinence (26). In a study of 1932 men who had the
International Prostate Symptom Score assessed before
implant and out to 10 years, the addition of EBRT was
found to significantly increase the score ( p5 0.011) within
the first 2 years after implantation but not after that (27).
Sarosdy (21) found an increased need for TURP, document-
ing the procedure in 14.5% of patients after combination vs.
5% for implant alone ( p 5 0.029). Postimplant transure-
thral resection of the prostate (TURP) greatly increases
the risk of urinary incontinence. Kollmeier et al. (28) re-
ported TURP in 38/2050 implant patients (2%) and found
seven (38%) with incontinence. There was no significant
correlation between incontinence risk based on the dose
to 90% of prostate volume ( p 5 0.32) or the dose to
30% or 5 cm2 of urethral volume ( p5 0.30).Secondary cancers
Radiation therapy (RT) may be associated with a small
increased risk of in field SCs. Inherently, the risk may be
greater for combination therapy vs. monotherapy because
of the larger volume treated. Abdel-Wahab et al. (29) re-
viewed the 1973e2002 Surveillance, Epidemiology, and
End Results database and stratified patients into four
groups. He identified 67,719 patients who had undergone
RT only and 40,433 patients who had not undergone RT
or surgery (Group 1, no RT, no surgery). EBRT (Group
2) was the most common RT modality and was given to
48,400 patients. Brachytherapy alone (Group 3) or in
combination with EBRT (Group 4) was given to 10,223
and 9096 patients, respectively. The overall incidence of
secondary primary cancers was 8.8% in patients who had
received RT alone and in 7.9% patients who did not
undergo RT. Among the RT groups, the greatest percentage
(10.3%) of secondary primary cancers was seen in the
EBRT (Group 2), followed by Group 4 (combination) at
5.7%. The lowest percentage was in the brachytherapy
(Group 3) at 4.7%. All differences were statistically signif-
icant. On the other hand, Zelefsky et al. (30) found no
increase in SC in 2658 patients treated with radical prosta-
tectomy (n 5 1348), EBRT (n 5 897), or brachytherapy
(n 5 413).
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There is little controversy that EBRT (IMRT) is costlier
than brachytherapy. Shah et al. (31) compared the costs of
permanent brachytherapy, high dose radiotherapy, and
IMRT and found reimbursement at $9938, $17,514, and
$29,356, respectively. Nguyen et al. (32) assessed temporal
trends in utilization and impact on national health care
spending for the different treatments for prostate cancer
from 2002 to 2005. For EBRT, IMRT utilization increased
substantially (28.7% vs. 81.7%; p!0.001), and for men
receiving brachytherapy, supplemental IMRT increased
significantly (8.5% vs. 31.1%; p!0 .001). The mean incre-
mental cost of IMRT vs. 3D-CRT was $10,986 (in 2008
dollars); of brachytherapy plus IMRT vs. brachytherapy
plus 3D-CRT was $10,789. Cooperberg et al. (33) per-
formed a cost utility analysis for the different treatments.
Direct medical and lifetime costs for brachytherapy
compared with combination were $14,106 vs. $29,142
and $32,553 vs. $43,553 ( p!0.001).Conclusions
Brachytherapy alone seems to be as effective as combi-
nation therapy in treating intermediate-risk prostate cancer.
While most data support the use of implant alone, delivered
radiation doses should beO140 Gy (I-125). Long-term data
suggest that BED may need to be greater than 180 Gy2 (I-
125 D90 O190 Gy). The addition of EBRT may increase
rectal toxicity, erectile dysfunction, and risk of inconti-
nence. The cost of treatment is markedly increased when
combination therapy is used. Brachytherapists should
consider implant alone as the preferred management option
for intermediate-risk prostate cancer.References
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